0001415889-24-009625.txt : 20240401 0001415889-24-009625.hdr.sgml : 20240401 20240401212828 ACCESSION NUMBER: 0001415889-24-009625 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240328 FILED AS OF DATE: 20240401 DATE AS OF CHANGE: 20240401 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Zinda Michael CENTRAL INDEX KEY: 0001815366 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39335 FILM NUMBER: 24812002 MAIL ADDRESS: STREET 1: C/O REPARE THERAPEUTICS INC. STREET 2: 7210 FREDERICK-BANTING, SUITE 100 CITY: ST-LAURENT STATE: A8 ZIP: H4S 2A1 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Repare Therapeutics Inc. CENTRAL INDEX KEY: 0001808158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7171 FREDERICK BANTING STREET 2: SUITE 270, BUILDING 2 CITY: SAINT-LAURENT STATE: A8 ZIP: H4S 1Z9 BUSINESS PHONE: (857) 412-7018 MAIL ADDRESS: STREET 1: 7171 FREDERICK BANTING STREET 2: SUITE 270, BUILDING 2 CITY: SAINT-LAURENT STATE: A8 ZIP: H4S 1Z9 4 1 form4-04022024_010422.xml X0508 4 2024-03-28 0001808158 Repare Therapeutics Inc. RPTX 0001815366 Zinda Michael C/O REPARE THERAPEUTICS INC. ST-LAURENT A8 H4S 1Z9 QUEBEC, CANADA false true false false EVP, CHIEF SCIENTIFIC OFFICER 1 Common Shares 2024-03-28 4 S 0 450 4.64 D 72318 D Common Shares 2024-04-01 4 S 0 410 4.66 D 71908 D This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 22, 2023. On January 30, 2023, the holder was granted 24,550 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on February 1, 2023, of which 8,183 of these RSUs vested on January 30, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.38 to $4.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.53 to $4.76 inclusive. /s/ Steve Forte, Attorney-in-Fact 2024-04-01